Stada Arz acquires UK branded product company

28 November 2016

Through its UK subsidiary, German drugmaker Stada Arzneimittel (SAZ: Xetra) has acquired family-owned UK based branded product company. Financial terms of the transaction were not disclosed.

The company, Natures Aid, is an established manufacturer of vitamins, minerals, food supplements and herbal products distributed under the Natures Aid brand. Until 2020, the global dietary supplement market is expected to grow by about 5% annually. Over the past years, the company posted double-digit sales growth annually (three-year-compound annual growth rate: ~14%).

Natures Aid, based in Preston, UK, was founded in 1981 and currently has around 60 employees. In the financial year July 2015 to June 2016 Nature Aid posted sales of £7.3 million (around $9 million), of which about 80% are generated in UK and 20% in more than 40 countries worldwide. Earnings before interest, taxes, depreciation and amortization (EBITDA) were £1.9 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK